For the upfront adjuvant therapy of postmenopausal estrogen receptor–positive breast cancer, the third-generation aromatase inhibitors (ais) have shown a more favourable overall risk–benefit profile than has tamoxifen. This evidence concerns the gene CYP19A1 and breast cancer.